- Home
- WLYB vs BEAM Comparison
WLYB vs BEAM Comparison
Compare WLYB & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLYB
- BEAM
- Stock Information
- Founded
- WLYB 1807
- BEAM 2017
- Country
- WLYB United States
- BEAM United States
- Employees
- WLYB N/A
- BEAM N/A
- Industry
- WLYB Books
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLYB Consumer Discretionary
- BEAM Health Care
- Exchange
- WLYB Nasdaq
- BEAM Nasdaq
- Market Cap
- WLYB 2.0B
- BEAM 2.3B
- IPO Year
- WLYB N/A
- BEAM 2020
- Fundamental
- Price
- WLYB $44.80
- BEAM $22.21
- Analyst Decision
- WLYB
- BEAM Strong Buy
- Analyst Count
- WLYB 0
- BEAM 11
- Target Price
- WLYB N/A
- BEAM $50.50
- AVG Volume (30 Days)
- WLYB 764.0
- BEAM 2.3M
- Earning Date
- WLYB 03-06-2025
- BEAM 05-06-2025
- Dividend Yield
- WLYB 3.15%
- BEAM N/A
- EPS Growth
- WLYB N/A
- BEAM N/A
- EPS
- WLYB 0.75
- BEAM N/A
- Revenue
- WLYB $1,703,491,000.00
- BEAM $63,518,000.00
- Revenue This Year
- WLYB N/A
- BEAM N/A
- Revenue Next Year
- WLYB $1.13
- BEAM $6.32
- P/E Ratio
- WLYB $57.94
- BEAM N/A
- Revenue Growth
- WLYB N/A
- BEAM N/A
- 52 Week Low
- WLYB $35.68
- BEAM $20.84
- 52 Week High
- WLYB $52.90
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- WLYB 64.29
- BEAM 38.64
- Support Level
- WLYB $43.99
- BEAM $21.60
- Resistance Level
- WLYB $44.93
- BEAM $24.53
- Average True Range (ATR)
- WLYB 0.37
- BEAM 1.64
- MACD
- WLYB 0.19
- BEAM -0.24
- Stochastic Oscillator
- WLYB 28.72
- BEAM 8.85
About WLYB John Wiley & Sons Inc.
John Wiley & Sons Inc is one of the world's greatest publishers and a trusted leader in research and learning. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.